File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Transforming growth factor (TGF)-beta1 gene common polymorphisms and plasma TGF-beta1 levels in patients with lung cancer

TitleTransforming growth factor (TGF)-beta1 gene common polymorphisms and plasma TGF-beta1 levels in patients with lung cancer
Authors
Issue Date2004
PublisherWiley-Blackwell Publishing Asia
Citation
The 9th Congress of the Asian Pacific Society of Respirology, Hong Kong, 10-13 December 2004. In Respirology, 2004, v. 9 n. S3, p. A120 Abstract no. 197 How to Cite?
AbstractTransforming growth factor (TGF)-b1 is known to regulate many cellular processes, including cell proliferation, differentiation, and apoptosis. Plasma TGF-b1 levels has been shown to be elevated in patients with lung cancer. In this study, we test the association of the polymorphisms at 2 loci, i.e. nucleotide position -509 in the promoter region (C-509T), and nucleotide position 869 relative to the transcription initiation site (T869C) of the TGF-b1 gene using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and measure the plasma TGF-b1 levels. TGF-b1 genotype and allele frequencies were not significantly different for patients with lung cancer (n = 102) and controls (nonsmokers, n = 140 or smokers, n = 116). The odds ratio of the TGF-b1 C allele at nucleotide position 869 was 0.51 (95% confidence interval 0.25 to 1.06; P = 0.0827) for patients and nonsmoking controls and 0.49 (95% confidence interval 0.23 to 1.03; P = 0.0702) for patients and smoking controls in a dominant model (TC + CC versus TT), close to reach significant level. The patients group showed significant higher plasma TGF-b1 levels across different genotypes (1852 ± 123 pg/ml vs. 3422 ± 158 pg/ml for nonsmoking controls and patients respectively). There was no difference in plasma TGF-b1 levels between smoking controls and patients. Our results suggest that TGF-b1 polymorphisms do not play a role in the pathogenesis of lung cancer, even though there remains the possibility of a lower incidence of lung cancer for polymorphism at nucleotide position 869, which need further investigation. (Supported by a University of Hong Kong, URC/CRCG Research Grant.)
Persistent Identifierhttp://hdl.handle.net/10722/101243
ISSN
2015 Impact Factor: 3.078
2015 SCImago Journal Rankings: 1.157

 

DC FieldValueLanguage
dc.contributor.authorHo, SPen_HK
dc.contributor.authorChan-Yeung, MMWen_HK
dc.contributor.authorTsang, KWTen_HK
dc.contributor.authorIp, MSMen_HK
dc.contributor.authorLam, WKen_HK
dc.contributor.authorMak, JCWen_HK
dc.date.accessioned2010-09-25T19:41:41Z-
dc.date.available2010-09-25T19:41:41Z-
dc.date.issued2004en_HK
dc.identifier.citationThe 9th Congress of the Asian Pacific Society of Respirology, Hong Kong, 10-13 December 2004. In Respirology, 2004, v. 9 n. S3, p. A120 Abstract no. 197en_HK
dc.identifier.issn1323-7799-
dc.identifier.urihttp://hdl.handle.net/10722/101243-
dc.description.abstractTransforming growth factor (TGF)-b1 is known to regulate many cellular processes, including cell proliferation, differentiation, and apoptosis. Plasma TGF-b1 levels has been shown to be elevated in patients with lung cancer. In this study, we test the association of the polymorphisms at 2 loci, i.e. nucleotide position -509 in the promoter region (C-509T), and nucleotide position 869 relative to the transcription initiation site (T869C) of the TGF-b1 gene using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and measure the plasma TGF-b1 levels. TGF-b1 genotype and allele frequencies were not significantly different for patients with lung cancer (n = 102) and controls (nonsmokers, n = 140 or smokers, n = 116). The odds ratio of the TGF-b1 C allele at nucleotide position 869 was 0.51 (95% confidence interval 0.25 to 1.06; P = 0.0827) for patients and nonsmoking controls and 0.49 (95% confidence interval 0.23 to 1.03; P = 0.0702) for patients and smoking controls in a dominant model (TC + CC versus TT), close to reach significant level. The patients group showed significant higher plasma TGF-b1 levels across different genotypes (1852 ± 123 pg/ml vs. 3422 ± 158 pg/ml for nonsmoking controls and patients respectively). There was no difference in plasma TGF-b1 levels between smoking controls and patients. Our results suggest that TGF-b1 polymorphisms do not play a role in the pathogenesis of lung cancer, even though there remains the possibility of a lower incidence of lung cancer for polymorphism at nucleotide position 869, which need further investigation. (Supported by a University of Hong Kong, URC/CRCG Research Grant.)-
dc.languageengen_HK
dc.publisherWiley-Blackwell Publishing Asia-
dc.relation.ispartofRespirologyen_HK
dc.titleTransforming growth factor (TGF)-beta1 gene common polymorphisms and plasma TGF-beta1 levels in patients with lung canceren_HK
dc.typeConference_Paperen_HK
dc.identifier.emailChan, MMW: mmwchan@hku.hken_HK
dc.identifier.emailTsang, KWT: kwttsang@hku.hken_HK
dc.identifier.emailIp, MSM: msmip@hku.hken_HK
dc.identifier.emailLam, WK: lamwk@hku.hken_HK
dc.identifier.emailMak, JCW: judymak@HKUCC.hku.hken_HK
dc.identifier.authorityIp, MSM=rp00347en_HK
dc.identifier.authorityMak, JCW=rp00352en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1440-1843.2004.00673.x-
dc.identifier.hkuros98143en_HK
dc.identifier.volume9en_HK
dc.identifier.issueS3en_HK
dc.identifier.spageA120en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats